Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Adam S. Crystal"'
Autor:
Alan Huang, Andre Mignault, Minjie Zhang, Yi Yu, Leanne Ahronian, Xinyuan Wu, Chengyin Min, Alborz Bejnood, Nikitha Das, Preksha Shahagadkar, Alice W Tsai, Lauren Flynn, Heather DiBenedetto, Adam S Crystal
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/c78766530906457e87da99ccadcc2ae3
Autor:
Jeffrey A. Engelman, Alice T. Shaw, Jennifer L. Harris, Makoto Nishio, Naoya Fujita, Elizabeth L. Lockerman, Sidra Mahmood, Peter McNamara, Su Hua, Xiuying Sun, Frank Sun, Shailaja Kasibhatla, Jie Li, AnneMarie C. Pferdekamper, Sungjoon Kim, Noriko Yanagitani, Mark M. Awad, Pierre-Yves Michellys, Adam S. Crystal, Justin F. Gainor, Christian C. Lee, Ryohei Katayama, Nanxin Li, Luc Friboulet
PDF file 70K, This table contains the IC50 values of in vitro cell survival assay for crizotinib or ceritinib in engineered EML4-ALK mutant Ba/F3 cells corresponding to Fig 4A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbbad5b9475ebf740303ecca033f51a2
https://doi.org/10.1158/2159-8290.22530507.v1
https://doi.org/10.1158/2159-8290.22530507.v1
Autor:
Jeffrey A. Engelman, Alice T. Shaw, Jennifer L. Harris, Makoto Nishio, Naoya Fujita, Elizabeth L. Lockerman, Sidra Mahmood, Peter McNamara, Su Hua, Xiuying Sun, Frank Sun, Shailaja Kasibhatla, Jie Li, AnneMarie C. Pferdekamper, Sungjoon Kim, Noriko Yanagitani, Mark M. Awad, Pierre-Yves Michellys, Adam S. Crystal, Justin F. Gainor, Christian C. Lee, Ryohei Katayama, Nanxin Li, Luc Friboulet
PDF file 135K, Figure S1 contains data about Ceritinib specificity and potency on crizotinib na?ve EML4-ALK wild-type cells. Figure S2 contains the Cell survival curves of H3122 CR1, MGH021-4 and MGH045 cells following treatment with Crizotinib or ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ef66a8df7dccfca8800c87972d78cb6
https://doi.org/10.1158/2159-8290.22530510
https://doi.org/10.1158/2159-8290.22530510
Autor:
Jeffrey A. Engelman, Alice T. Shaw, Jennifer L. Harris, Makoto Nishio, Naoya Fujita, Elizabeth L. Lockerman, Sidra Mahmood, Peter McNamara, Su Hua, Xiuying Sun, Frank Sun, Shailaja Kasibhatla, Jie Li, AnneMarie C. Pferdekamper, Sungjoon Kim, Noriko Yanagitani, Mark M. Awad, Pierre-Yves Michellys, Adam S. Crystal, Justin F. Gainor, Christian C. Lee, Ryohei Katayama, Nanxin Li, Luc Friboulet
PDF file 100K, Legends for the supplementary figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0ea846b0c38725c52287939c9514120
https://doi.org/10.1158/2159-8290.22530513
https://doi.org/10.1158/2159-8290.22530513
Autor:
Alice T. Shaw, Adam S. Crystal
Related Article from Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer?
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cde38ece3ba15421c6b39df623f78fb
https://doi.org/10.1158/1078-0432.22455426.v1
https://doi.org/10.1158/1078-0432.22455426.v1
Autor:
Geoffrey I. Shapiro, Sudha Parasuraman, Adam S. Crystal, Jason R. Dobson, Alessandro Matano, Abhijit Chakraborty, Vincent Ribrag, Rashmi Chugh, Petronella O. Witteveen, John F. Gerecitano, Philippe A. Cassier, Jeffrey R. Infante
Purpose: Ribociclib (an oral, highly specific cyclin-dependent kinase 4/6 inhibitor) inhibits tumor growth in preclinical models with intact retinoblastoma protein (Rb+). This first-in-human study investigated the MTD, recommended dose for expansion
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3746c446298c4ce410e9f76687a7be09
https://doi.org/10.1158/1078-0432.c.6526139
https://doi.org/10.1158/1078-0432.c.6526139
Autor:
Geoffrey I. Shapiro, Sudha Parasuraman, Adam S. Crystal, Jason R. Dobson, Alessandro Matano, Abhijit Chakraborty, Vincent Ribrag, Rashmi Chugh, Petronella O. Witteveen, John F. Gerecitano, Philippe A. Cassier, Jeffrey R. Infante
Fig. S1. Waterfall plot of duration of exposure vs. best percentage change from baseline; Figure S2. Duration of exposure in patients with stable disease treated for at least four cycles; Figure S3. Duration of exposure, best percentage change in tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac42ce5e3cb4c041a4fa1a55e1022295
https://doi.org/10.1158/1078-0432.22465751.v1
https://doi.org/10.1158/1078-0432.22465751.v1
Autor:
Yanke Liang, Mathew E. Sowa, Katrina L. Jackson, Jeffrey R. Simard, Bridget Kreger, Ping Li, Laura Poling, Joelle Baddour, Andrew Good, Hongwei Huang, Scott Eron, Christopher G. Nasveschuk, Robert Yu, Mark Fitzgerald, Victoria Garza, Morgan W. O’Shea, Gesine Veits, Jeremy Y. Yap, Moses Moustakim, Ashley Hart, Roman V. Agafonov, Grace Sarkissian, Joe S. Patel, Richard Deibler, Kyle S. Cole, David Cocozziello, Fazlur Rahman, Andrew J. Phillips, Elizabeth Norton, Adam S. Crystal, Roy M. Pollock, Stewart L. Fisher
Publikováno v:
Cancer Research. 83:3425-3425
The BRAF kinase plays a critical role in the MAPK signaling pathway and is mutated in ~8% of all human cancers including melanoma (~60%), thyroid (~60%), and lung adenocarcinoma (~10%). The most common mutation in BRAF is V600E (Class I), which is fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4eb2b150c4dde824e5ce0d7e8249985a
https://doi.org/10.1158/1538-7445.am2023-3425
https://doi.org/10.1158/1538-7445.am2023-3425
Autor:
Alejandro Balbin, Serena Liao, Adam S. Crystal, Komal Jhaveri, C Terret, Sara Cresta, Qing Sheng, François Duhoux, Dejan Juric, Yoon Sim Yap, Rachel M. Layman, Giuseppe Curigliano
Publikováno v:
Cancer Research. 80:P4-10
Background: LSZ102 is an orally bioavailable selective estrogen receptor degrader (SERD) that inhibits estrogen receptor (ER) mediated gene transcription, induces receptor degradation, and blocks ER-dependent cell growth in preclinical models. This f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14967ca97311164409bb5c02d732b3ff
https://doi.org/10.1158/1538-7445.sabcs19-p4-10-07
https://doi.org/10.1158/1538-7445.sabcs19-p4-10-07
Autor:
Ashley A. Hart, Stewart L. Fisher, Christina S. Henderson, Scott J. Eron, David A. Proia, Roy M. Pollock, Prasoon Chaturvedi, James A. Henderson, S Perino, B. T Kreger, Christopher G. Nasveschuk, Adam S. Crystal, Andrew C. Good, Roman V. Agafonov, Marta Isasa, B Class, Michelle Mahler, R. J Kirby
Publikováno v:
Hematological Oncology. 39
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1ff2f3296781240789b3754e21f66e68
https://doi.org/10.1002/hon.145_2880
https://doi.org/10.1002/hon.145_2880